ABSTRACT
Thoracic aortic endovascular repair (TEVAR) has been shown to be an effective treatment for many thoracic aortic conditions over the past few years. Although there is no long-term data about the effectiveness of this radical and revolutionary new therapy, the intermediate results have been promising. Interestingly, while the initial applications of TEVAR have been in the elective treatment of thoracic aortic conditions, TEVAR may have its most profound benefit in the catastrophic presentations associated with acute aortic conditions. It is in the acute aortic condition that standard operative treatment has the highest mortality and morbidity rates.
